Skip to Primary Content
Skip to Footer
home
about
products & pipeline
Clinical Trials
Publications
newsroom
investors
Stock Information
Press Releases
Events & Presentations
SEC Filings
ESG
Financial Information
partners
careers
Afrezza.com
818.661.5000
careers
partners
investors
Stock Information
Press Releases
Events & Presentations
SEC Filings
ESG
Financial Information
newsroom
products & pipeline
Clinical Trials
Publications
about
News & Events
March 27, 2018
Improved Postprandial Glucose with Inhaled Technosphere Insulin Compared with Insulin Aspart in Patients with Type 1 Diabetes on Multiple Daily Injections: The STAT Study.
previous post
next post
×